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BACKGROUND: Biliary tract cancers are rare but fatal malignancies. Diabetes has been related to biliary stones, but its association with
biliary tract cancers is less conclusive.
METHODS: In a population-based case–control study of 627 cancers, 1037 stones, and 959 controls in Shanghai, China, we examined
the association between diabetes and the risks of biliary tract cancer and stones, as well as the effect of potential mediating factors,
including serum lipids and biliary stones (for cancer), contributing to the causal pathway from diabetes to biliary diseases.
RESULTS: Independent of body mass index (BMI), diabetes was significantly associated with gallbladder cancer and biliary stones
((odds ratio (OR) (95% confidence interval)¼2.6 (1.5–4.7) and 2.0 (1.2–3.3), respectively). Biliary stones and low serum levels of
high-density lipoprotein (HDL) were significant mediators of the diabetes effect on gallbladder cancer risk, accounting for 60 and 17%
of the diabetes effect, respectively. High-density lipoprotein was also a significant mediator of the diabetes effect on biliary stones,
accounting for 18% of the diabetes effect.
CONCLUSIONS: Independent of BMI, diabetes is a risk factor for gallbladder cancer, but its effect is mediated in part by biliary stones and
serum HDL levels, suggesting that gallbladder cancer risk may be reduced by controlling diabetes, stones, and HDL levels.
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Biliary tract cancers, including cancers of the gallbladder,
extrahepatic bile duct, and ampulla of Vater, are rare but fatal
malignancies (Hsing et al, 2006). Other than biliary stones, little is
known about the aetiology of biliary tract cancers, although
obesity, hyperlipidemia, and diabetes have been suggested as risk
factors (Hsing et al, 2007, 2008b; Andreotti et al, 2008).
Diabetes has been associated with a higher risk of biliary stones
in some, but not all, studies (Pagliarulo et al, 2004; Festi et al,
2008). Diabetes affects serum lipid levels (Abrams et al, 1982;
Goldberg, 2001), which has a critical role in the development
of biliary stones (Carey, 1993; Singh et al, 1997). At present, it
is unclear whether the association between diabetes and biliary
stones is independent of serum lipid levels and whether the
diabetes effect on biliary tract cancer is mediated through serum
lipid levels and biliary stones.
To clarify these relationships, we examined the association
between diabetes and the risks of biliary stones and cancer in
Shanghai, China, where the incidence rates of biliary tract cancer
have risen sharply in recent decades. We also assessed the
potential mediating effects of serum lipid levels and biliary stones
on these associations.
MATERIALS AND METHODS
Details of the study have been reported elsewhere (Hsing et al,
2008a,b). Briefly, between 1997 and 2001, patients newly diagnosed
with primary biliary tract cancers were recruited through a rapid-
reporting system in 42 hospitals in Shanghai. During the study
period, the rapid-reporting system identified more than 95% of
incident biliary tract cancer patients in Shanghai. Biliary tract
cancer cases were confirmed by histopathological assessment
(70% of cases) or by medical or surgical records or imaging data
(30% of cases). Cancer-free biliary stone patients were identified
from the same hospitals as cancer cases, and frequency matched to
the index cancer case on age (5-year groups), sex, and diagnosing
hospital. Biliary stone cases were confirmed using abdominal
ultrasound, endoscopic retrograde cholangiopancreatography,
medical or surgical records, or pathologic specimens for those
who underwent a cholecystectomy. Healthy subjects without
biliary tract cancer were randomly selected from the Shanghai
Resident Registry, and were frequency matched to the index cancer
case on age (5-year groups) and sex. Biliary stone status for biliary
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ytract cancer cases was determined by self-report (22.7%) or
medical records (77.3%), and for population controls it was based
on self-report (22.7%) or abdominal ultrasound (77.3%). Partici-
pation rates were 95% among cases and 82% among controls.
Written informed consents were obtained from all participants,
and the study was approved by the institutional review boards of
the US National Cancer Institute (NCI) and the Shanghai Cancer
Institute (SCI), China.
In-person interviews were conducted by trained interviewers
using a structured questionnaire to obtain information on
demographic characteristics, lifestyle factors, and medical his-
tories. Cancer and stone cases were interviewed within 3 weeks
after diagnosis. The accuracy of the interviews was assessed
by randomly selecting 5% of the subjects to be re-interviewed
3 months after the initial interview. Concordance between the two
interviews was greater than 90%.
Overnight fasting blood samples were collected from over 80%
of the participants who gave consent. Within 4h of collection,
samples were transported to the SCI for processing, and were later
shipped to the NCI repository on dry ice by express mail.
Fasting serum lipid levels were measured for all subjects who
donated overnight fasting blood samples. Blood lipids were
measured at the Laboratory of Biochemistry, Institute of Cardio-
vascular Diseases, Zhongshan Hospital, Shanghai Medical
University (Fudan University).
Statistical analysis
Fisher exact test (when the data were sparse) and w
2 statistics were
used for the bivariate comparisons. Ampulla of Vater and bile duct
cancers were compared with all population controls (n¼959),
whereas gallbladder cancer was compared with population
controls without cholecystectomy (n¼902). Biliary stones were
compared with population controls without stones (n¼735). The
association between diabetes and biliary tract cancers and stones
was assessed using multivariable unconditional logistic regression
to calculate the odds ratio (OR) and 95% confidence interval (95%
CI) adjusting for potential confounders, including age, sex, body
mass index (BMI), waist-to-hip ratio (WHR), education, and
aspirin use. Body mass index was grouped according to the WHO
classification for Asian populations as normal (18.5–o23kgm
 2),
overweight (23–o25kgm
 2), and obese (X25kgm
 2) (WHO/
IASO/IOTF, 2000; WHO Expert Consultation, 2004). Lipid levels
were classified as high triglycerides (X1.7mmoll
 1), low high-
density lipoprotein (HDL) (o1.04mmoll
 1), and high low-density
lipoprotein (LDL) (X4.14mmoll
 1) based on the Joint Committee
for Developing Chinese Guidelines on Prevention and Treatment
of Dyslipidemia in Adults (JCDCG) (2007). Diabetes is based on
self-reported history of diabetes.
Mediation modelling was used to assess the percent of total
diabetes effect that is mediated by each potential mediating factor.
A mediating factor is an intermediate variable in the causal
pathway between an independent variable (diabetes) and depen-
dent variable (biliary tract cancer or stones). We examined the
potential mediating factors (biliary stones (on cancer risk), total
triglycerides, LDL, and HDL (for cancer and stone risk)), which are
risk factors for biliary tract cancers/stones and have also been
linked to diabetes (Hsing et al, 2007; Andreotti et al, 2008). Body
mass index was not evaluated as a mediator, as obesity probably
precedes the development of diabetes and therefore is not in the
causal pathway between diabetes and biliary diseases. Instead, BMI
was evaluated as a confounder. Structural equation modelling was
used to calculate the mediated effect and its statistical significance
(MacKinnon et al, 2007; Preacher and Hayes, 2008). We ran two
mediation analyses: (1) single mediation models (unadjusted, a
model that has single mediator), (2) multiple mediation model
(adjusted, to obtain the significance of individual mediators within
the context of a model that has multiple mediators simultaneously
and account for the biological direction between mediators).
Triglycerides, LDL, and HDL were used as continuous variables
in all mediation modelling. All analyses were conducted using
SAS 9.1(SAS Institute, Cary, NC, USA), and Mplus, version 5.
RESULTS
A total of 368 gallbladder cancer, 191 extrahepatic bile duct cancer,
and 68 ampulla of Vater cancer cases, as well as 1037 biliary stone
cases and 959 population-based controls, were included in the
study. Table 1 shows the characteristics of the study subjects by
case–control status.
Prevalence of self-reported diabetes (diagnosed by a doctor in
the past) was 8.1% in controls and 13.9, 10.5, and 7.4% in subjects
with cancers of the gallbladder, bile duct, and ampulla of Vater,
respectively. Diabetes was associated with significant excess risks
of gallbladder cancer (OR¼2.6, 95% CI 1.5–4.7) and biliary stones
(OR¼2.0, 95% CI 1.2–3.3), but not with bile duct cancer or
ampulla of Vater cancer, after adjustment for age, sex, education,
BMI, WHR, duration of diabetes, and aspirin use (Table 2).
In single mediation models, HDL accounted for 17.6% of the
effect of diabetes on biliary stone risk (P¼0.02), and HDL and
biliary stones accounted for 22.3% (P¼0.03) and 44.3% of the
diabetes effect on gallbladder cancer risk. When HDL and biliary
stones were included in the same model, both factors together
explained 76.9% of the diabetes effect on gallbladder cancer risk
(Po0.0001), with the percent mediated as: (i) diabetes to biliary
stones to gallbladder cancer (54.8%), (ii) diabetes to HDL to
gallbladder cancer (16.5%), and (iii) diabetes to HDL to biliary
stones to gallbladder cancer (5.6%); therefore, 60.4% of the overall
diabetes effect on gallbladder cancer risk was mediated through
stones (Table 3 and Figure 1).
DISCUSSION
Data from this population-based case–control study suggest that,
independent of BMI, diabetes was associated with excess risks of
gallbladder cancer and biliary stones. About 60% of the effect of
diabetes on biliary tract cancer was mediated by gallstones and
17% by HDL. High-density lipoprotein is also a significant
mediator for gallstones, accounting for 18% of the diabetes effect
on gallstone risk.
In our study, independent of BMI, diabetes was associated with a
two-fold risk of biliary stones, which is consistent with some
previous studies (Chapman et al, 1996; Attili et al, 1997; De Santis
et al, 1997; Pagliarulo et al, 2004), but not all (Jorgensen, 1989;
Loria et al, 1994). The inconsistency in these results may be due, in
part, to differences in methodology (e.g., patient selection),
misclassification of diabetes status (on the basis of self-reported
data), or incomplete adjustment for confounding (Feldman and
Feldman, 1954; Jorgensen, 1989; Loria et al, 1994).
The association between diabetes and biliary stones is biologi-
cally plausible, as diabetes has been related to several key factors
important in the process of stone formation, including lithogenic
bile that is supersaturated with cholesterol, particularly in subjects
with dyslipidemia and after initiation of insulin therapy (Abrams
et al, 1982; Stone and Van Thiel, 1985). Our observation that HDL
mediated the effect of diabetes on biliary stones further suggests
that diabetes-related dyslipidemia, primarily manifested as lower
levels of plasma HDL (Goldberg, 2001), has an important role in
predisposing to biliary stones. Low levels of circulating HDL are
associated with increased hepatic secretion of cholesterol and
diminished secretion of bile salts and phospholipids that
contribute to lowering the solubility of cholesterol in bile (Carey,
1993; Volzke et al, 2005). Thus, it is possible that the risk of biliary
stones may be reduced by increasing circulating levels of HDL
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with diabetes.
Consistent with some previous studies, but not all (Adami et al,
1996; Welzel et al, 2007; Grainge et al, 2009), independent of
BMI, we found an excess risk of gallbladder cancer in subjects
with diabetes. In the past, it has not been clear whether the
diabetes–gallbladder cancer association is independent of gall-
stones, given the relationship of diabetes to gallstones, and of
Table 1 Selected characteristics of study subjects by case–control status
Population controls
Biliary tract cancers
All Gallbladder
a Extrahepatic bile duct
b Ampulla of Vater
b Biliary tract stones
c
N (%) N (%) N (%) N (%) N (%)
Total 959 (100) 368 (100) 191 (100) 68 (100) 1037 (100)
Age at interview
34–49 71 (7.4) 29 (7.9) 18 (9.4) 4 (5.9) 200 (19.3)
50–64 326 (34.0) 116 (31.5) 59 (30.9) 22 (32.4) 405 (39.1)
65–74 562 (58.6) 223 (60.6) 114 (59.6) 42 (61.7) 432 (41.6)
Gender
Male 373 (38.9) 99 (26.9) 99 (51.8) 37 (54.4) 390 (37.6)
Female 586 (61.1) 269 (73.1) 92 (48.2) 31 (45.6) 647 (62.4)
Education
None/primary 396 (41.3) 198 (53.8) 86 (45.0) 29 (42.7) 317 (30.6)
Middle/high school 423 (44.1) 129 (35.1) 74 (38.7) 31 (45.6) 537 (51.8)
College or higher 140 (14.6) 41 (11.1) 31 (16.2) 8 (11.7) 183 (17.6)
Smoking
d
No 674 (70.3) 278 (75.8) 115 (60.2) 38 (55.9) 754 (72.7)
Yes 285 (29.7) 89 (24.2) 76 (39.8) 30 (44.1) 283 (27.3)
Alcohol use
e
No 760 (79.3) 316 (85.9) 141 (73.8) 53 (77.9) 869 (83.9)
Yes 198 (20.7) 52 (14.1) 50 (26.2) 15 (22.1) 167 (16.1)
Body mass index
f
o18.5 79 (8.3) 17 (4.7) 8 (4.2) 1 (1.47) 44 (4.3)
18.5–22.9 404 (42.2) 130 (35.6) 86 (45.5) 29 (42.7) 350 (33.8)
23.0–24.9 197 (20.5) 73 (20.0) 49 (25.9) 15 (22.1) 259 (25.0)
X25.0 278 (29.0) 145 (39.7) 46 (24.3) 23 (33.8) 382 (36.9)
Waist-to-hip ratio
g
p0.81 238 (24.8) 38 (12.2) 21 (13.9) 10 (16.1) 163 (16.0)
0.81–0.852 234 (24.4) 48 (15.4) 24 (15.9) 10 (16.1) 200 (19.7)
0.853–0.897 249 (26.0) 93 (29.8) 40 (26.5) 15 (24.2) 272 (26.8)
40.897 238 (24.8) 133 (42.6) 66 (43.7) 27 (43.6) 382 (37.6)
Selected medical history
Diabetes mellitus
No 881 (91.9) 316 (86.1) 171 (89.5) 63 (92.7) 925 (89.3)
Yes 78 (8.1) 51 (13.9) 20 (10.5) 5 (7.3) 111 (10.7)
Hypertension
No 553 (57.7) 230 (62.5) 130 (68.1) 48 (70.6) 695 (67.0)
Yes 406 (42.3) 138 (37.5) 61 (31.9) 20 (29.4) 342 (33.0)
Gallstones
No 735 (76.6) 60 (16.3) 64 (33.5) 32 (47.1) 0 (0.0)
Yes 224 (23.4) 308 (83.7) 127 (66.5) 36 (52.9) 1037 (100.0)
Triglycerides
h (mmoll
 1)
o1.7 635 (74.0) 150 (56.8) 52 (36.9) 30 (54.6) 637 (64.9)
X1.7 223 (26.0) 114 (43.2) 89 (63.1) 25 (45) 344 (35.1)
HDL
h (mmoll
 1)
o1.04 292 (34.0) 206 (78.0) 114 (81.4) 46 (83.6) 603 (61.5)
X1.04 566 (66.0) 58 (23.0) 26 (18.6) 9 (16.4) 378 (38.5)
LDL
h (mmoll
 1)
o4.14 776 (90.6) 231 (87.5) 117 (83.0) 44 (80.0) 904 (92.7)
X4.14 81 (9.4) 33 (12.5) 24 (17.0) 11 (20.0) 71 (7.3)
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aGallbladder cancer cases were compared with population controls without history of previous
cholecystectomy (n¼902).
bAmpulla of Vater and extrahepatic bile duct cancer cases were compared with all population control (n¼959).
cBiliary stone cases were compared
with controls without biliary stones (n¼735).
dEver smoked at least one cigarette per day for 6 months or longer.
eEver drank alcoholic beverages regularly.
fBMI¼weight (kg)/
height (m)
2 5 years before interview. Categories on the basis of WHO classification for Asians.
gMeasured at interview, quartile cutoff points were based on distribution among
population controls without history of previous cholecystectomy.
hCutoff on the basis of the Joint Committee for Developing Chinese Guidelines on Prevention and Treatment
of Dyslipidemia in Adults.
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showed that, irrespective of gallstone status, diabetes is associated
with gallbladder cancer, suggesting that diabetes may increase the
risk of gallbladder cancer independent of the lipid-stone
pathogenesis. Indeed, our mediation analysis indicated that
biliary stones explained 60% of the effect of diabetes on gall-
bladder cancer, whereas HDL accounted for 18%, and only 6% was
attributed to HDL via biliary stones pathway. These findings
support the role of gallstones in gallbladder cancer aetiology
among diabetics. In addition, our findings suggest that HDL may
function as a mediator through pathways other than stones, such
as inflammation (von Eckardstein et al, 2005). Both in vitro and in
vivo studies have shown that low levels of HDL may be related to
increased oxidation of LDL, which is associated with increased
reactive oxygen species and proinflammatory cytokines (Benitez
et al, 2006).
Our study has several strengths, including its population-
based design, large sample size, high response rate, and
thorough evaluation of cancer and stone diagnoses, all of
which serve to minimise selection bias and misclassification of
outcomes. Limitations of the study should be noted as well.
Misclassification of diabetes from self-reported information is
likely but should be minimal, as 86% of the subjects who reported
having diabetes also reported using antidiabetes treatment. In
addition, only 2.2% of the controls who reported no history of
diabetes had elevated serum glucose levels, suggesting that few
subjects had asymptomatic or undiagnosed diabetes at the time of
interview. However, we had no information on cholesterol-
lowering drugs, and thus we cannot control for this effect in our
analysis of HDL.
In summary, our study revealed an increased risk of gallbladder
cancer and biliary stones among diabetics, independent of obesity
and other putative risk factors. Both biliary stones and low HDL
levels were significant mediators of the diabetes effect on the risk
of gallbladder cancer, whereas HDL was a significant mediator of
the diabetes effect on biliary stones. These findings need to be
confirmed in future studies.
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Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for biliary tract cancer and biliary stones in relation to diabetes mellitus
a
Biliary tract cancers
Gallbladder
b Extrahepatic bile Duct
c Ampulla of Vater
c Biliary tract stones
d
Diabetes
mellitus
a
Control,
N
Cancer,
N
OR
(95% CI)
e
Control,
N
Cancer,
N
OR
(95% CI)
e
Control,
N
Cancer,
N
OR
(95% CI)
e
Control,
N
Cancer,
N
OR
(95% CI)
e
No 834 316 1.0 881 171 1.0 881 63 1.0 688 925 1.0
Yes 68 51 2.63
(1.47–4.68)
78 20 0.79
(0.30–2.07)
78 5 0.74
(0.18–3.07)
47 111 2.03
(1.24–3.33)
aSelf-reported diabetes.
bGallbladder cancer cases were compared with population controls without history of previous cholecystectomy.
cExtrahepatic bile duct and ampulla of
Vater cancer cases compared with all population controls.
dBile duct and gallbladder stone cases compared with controls without biliary stones.
eAdjusted for age, sex, education,
diabetes duration, body mass index, waist-to-hip ratio, and aspirin use.
Table 3 Mediation of the effect of diabetes mellitus
a on biliary
tract cancers and stones through HDL, LDL, total triglycerides, and
gallstones
Biliary stones Gallbladder cancer
Percent
mediated
b P-value
c
Percent
mediated
b P-value
c
Mediators in single mediation models
d
HDL 17.6% 0.02 22.3% 0.03
LDL NA
e 0.51 NA
e 0.57
Total triglycerides NA
e 0.09 NA
e 0.10
Biliary stones NA
f NA
f 44.3% o0.0001
Mediators in multiple mediation model
g
HDL 16.5% 0.03
HDL to biliary stones 5.6% o0.0001
Biliary stones 54.8% 0.02
Total mediated effects
h 76.9% o0.0001
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aSelf-reported diabetes.
bPercent of total diabetes effect that is mediated.
cCalculated
using 5000 bootstrap samples.
dCalculated using structural equation modelling.
eNot applicable because the pathway is not significant.
fNot applicable because
biliary stones is the outcome.
gCalculated using structural equation modelling.
HDL adjusted for biliary stones, and vice versa.
hSum of percent mediated by different
mediators.
Total effect
Direct effect
GBC
Stones
Diabetes
HDL
A2: –0.060
A1: 0.431
C′ 0.159
B2: –1.898
B1: 0.880
C 0.691 GBC Diabetes
M
:
 
–
0
.
7
4
7
Percent mediated through stones =A1×B1/C= 54.8%
Percent mediated through HDL=A2×B2/C= 16.5%
Percent mediated through HDL to stones =A2×M×B1/C=5.6%
Figure 1 Results of multiple mediation analysis.
Diabetes and biliary tract cancer and stones risk
FM Shebl et al
118
British Journal of Cancer (2010) 103(1), 115–119 & 2010 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yREFERENCES
Abrams JJ, Ginsberg H, Grundy SM (1982) Metabolism of cholesterol
and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31:
903–910
Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, Wolk A,
McLaughlin JK, Fraumeni Jr JF (1996) Excess risk of primary liver
cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:
1472–1477
Andreotti G, Chen J, Gao YT, Rashid A, Chang SC, Shen MC, Wang BS,
Han TQ, Zhang BH, Danforth KN, Althuis MD, Hsing AW (2008) Serum
lipid levels and the risk of biliary tract cancers and biliary stones: a
population-based study in China. Int J Cancer 122: 2322–2329
Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, Capocaccia L,
Menotti A, Okolicsanyi L, Ricci G, Lalloni L, Mariotti S, Sama C,
Scafato E (1997) Factors associated with gallstone disease in the MICOL
experience. Multicenter Italian Study on Epidemiology of Cholelithiasis.
Hepatology 26: 809–818
Benitez S, Camacho M, Bancells C, Vila L, Sanchez-Quesada JL,
Ordonez-Llanos J (2006) Wide proinflammatory effect of electronegative
low-density lipoprotein on human endothelial cells assayed by a protein
array. Biochim Biophys Acta 1761: 1014–1021
Carey MC (1993) Pathogenesis of gallstones. Am J Surg 165: 410–419
Chapman BA, Wilson IR, Frampton CM, Chisholm RJ, Stewart NR, Eagar
GM, Allan RB (1996) Prevalence of gallbladder disease in diabetes
mellitus. Dig Dis Sci 41: 2222–2228
De Santis A, Attili AF, Ginanni Corradini S, Scafato E, Cantagalli A,
De Luca C, Pinto G, Lisi D, Capocaccia L (1997) Gallstones and diabetes:
a case-control study in a free-living population sample. Hepatology 25:
787–790
Feldman M, Feldman Jr M (1954) The incidence of cholelithiasis,
cholesterosis, and liver disease in diabetes mellitus: an autopsy study.
Diabetes 3: 305–307
Festi D, Dormi A, Capodicasa S, Staniscia T, Attili AF, Loria P, Pazzi P,
Mazzella G, Sama C, Roda E, Colecchia A (2008) Incidence of gallstone
disease in Italy: results from a multicenter, population-based Italian
study (the MICOL project). World J Gastroenterol 14: 5282–5289
Goldberg IJ (2001) Clinical review 124: diabetic dyslipidemia: causes and
consequences. J Clin Endocrinol Metab 86: 965–971
Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR (2009) The
antecedents of biliary cancer: a primary care case-control study in the
United Kingdom. Br J Cancer 100: 178–180
Hsing AW, Gao YT, Han TQ, Rashid A, Sakoda LC, Wang BS, Shen MC,
Zhang BH, Niwa S, Chen J, Fraumeni Jr JF (2007) Gallstones and the risk
of biliary tract cancer: a population-based study in China. Br J Cancer 97:
1577–1582
Hsing AW, Rashid A, Devesa SS, Fraumeni Jr JF (2006) Biliary tract cancer.
In Cancer Epidemiology and Prevention, Schottenfeld D, Fraumeni Jr JF
(eds) 3rd edn, pp 787–800. Oxford University Press Inc.: New York
Hsing AW, Sakoda LC, Rashid A, Andreotti G, Chen J, Wang BS, Shen MC,
Chen BE, Rosenberg PS, Zhang M, Niwa S, Chu L, Welch R, Yeager M,
Fraumeni Jr JF, Gao YT, Chanock SJ (2008a) Variants in inflammation
genes and the risk of biliary tract cancers and stones: a population-based
study in China. Cancer Res 68: 6442–6452
Hsing AW, Sakoda LC, Rashid A, Chen J, Shen MC, Han TQ, Wang BS,
Gao YT (2008b) Body size and the risk of biliary tract cancer:
a population-based study in China. Br J Cancer 99: 811–815
Joint Committee for Developing Chinese Guidelines on Prevention and
Treatment of Dyslipidemia in Adults (2007) [Chinese guidelines on
prevention and treatment of dyslipidemia in adults]. Zhonghua Xin Xue
Guan Bing Za Zhi 35: 390–419
Jorgensen T (1989) Gall stones in a Danish population. Relation to weight,
physical activity, smoking, coffee consumption, and diabetes mellitus.
Gut 30: 528–534
Loria P, Dilengite MA, Bozzoli M, Carubbi F, Messora R, Sassatelli R,
Bertolotti M, Tampieri A, Tartoni PL, Cassinadri M, Ciana MD,
Contemori M, Save N, Sordi B, Alimenti G, Fabrizi F, Buciuni A,
Carulli N (1994) Prevalence rates of gallstone disease in Italy. The
Chianciano population study. Eur J Epidemiol 10: 143–150
MacKinnon DP, Lockwood CM, Brown CH, Wang W, Hoffman JM (2007)
The intermediate endpoint effect in logistic and probit regression.
Clin Trials 4: 499–513
Pagliarulo M, Fornari F, Fraquelli M, Zoli M, Giangregorio F, Grigolon A,
Peracchi M, Conte D (2004) Gallstone disease and related risk factors in a
large cohort of diabetic patients. Dig Liver Dis 36: 130–134
Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for
assessing and comparing indirect effects in multiple mediator models.
Behav Res Methods 40: 879–891
Singh V, Zaidi SA, Singh VS (1997) Lipids in biliary lithogenesis. J Pak Med
Assoc 47: 253–255
Stone BG, Van Thiel DH (1985) Diabetes mellitus and the liver. Semin Liver
Dis 5: 8–28
Volzke H, Baumeister SE, Alte D, Hoffmann W, Schwahn C, Simon P, John U,
Lerch MM (2005) Independent risk factors for gallstone formation in a
region with high cholelithiasis prevalence. Digestion 71: 97–105
von Eckardstein A, Hersberger M, Rohrer L (2005) Current understanding
of the metabolism and biological actions of HDL. Curr Opin Clin Nutr
Metab Care 8: 147–152
Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA,
McGlynn KA (2007) Risk factors for intrahepatic and extrahepatic
cholangiocarcinoma in the United States: a population-based case-
control study. Clin Gastroenterol Hepatol 5: 1221–1228
WHO Expert Consultation (2004) Appropriate body-mass index for Asian
populations and its implications for policy and intervention strategies.
Lancet 363: 157–163
WHO/IASO/IOTF (2000) The Asia-Pacific Perspective: Redefining
Obesity and its Treatment Health Communications Australia Pty Ltd
(Full document available from: http://www.wpro.who.int/NR/rdonlyres/
0A35147B-B1D5-45A6-9FF2-F7D86608A4DE/0/Redefiningobesity.pdf)
Australia, Melbourne
Diabetes and biliary tract cancer and stones risk
FM Shebl et al
119
British Journal of Cancer (2010) 103(1), 115–119 & 2010 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y